<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2401">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552876</url>
  </required_header>
  <id_info>
    <org_study_id>CR-4582</org_study_id>
    <nct_id>NCT01552876</nct_id>
  </id_info>
  <brief_title>Comparative Clinical Evaluation of Soft Toric Lens Designs</brief_title>
  <official_title>Comparative Clinical Evaluation of Soft Toric Lens Designs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the initial fit of toric contact lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase I: Absolute Lens Rotation</measure>
    <time_frame>At 1-min after lens insertion during Phase I</time_frame>
    <safety_issue>No</safety_issue>
    <description>At 1-min after lens insertion, lens orientation position was assessed on a scale of 0-180 degree on both eyes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: Absolute Lens Rotation</measure>
    <time_frame>3 min after lens insertion during Phase I</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lens orientation position as assessed on a scale of 0-180 on both eyes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Time to Lens Settling</measure>
    <time_frame>5 minutes after lens insertion during Phase I</time_frame>
    <safety_issue>No</safety_issue>
    <description>With random insertion and natural blinking, the slit lamp video was used to measure the time of lens settling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Number of Blinks Until Settled</measure>
    <time_frame>Baseline to 5 minutes during Phase I</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of blinks for the right eye was counted until lens settling using headcam video.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Phase II: Absolute Rotation</measure>
    <time_frame>1-minute during Phase II</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absolute rotation of the lens (degrees) at 1-minute post-fit on both eyes. Filcon II 3 lens was only used for comparison in phase II of the study per study protocol.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Astigmatism</condition>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>etafilcon A / nelfilcon A / Filcon II 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nelfilcon A / etafilcon A / Filcon II 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>A daily wear contact lens</description>
    <arm_group_label>etafilcon A / nelfilcon A / Filcon II 3</arm_group_label>
    <arm_group_label>nelfilcon A / etafilcon A / Filcon II 3</arm_group_label>
    <other_name>1-DAY ACUVUE MOIST for Astigmatism</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nelfilcon A</intervention_name>
    <description>A daily wear contact lens</description>
    <arm_group_label>etafilcon A / nelfilcon A / Filcon II 3</arm_group_label>
    <arm_group_label>nelfilcon A / etafilcon A / Filcon II 3</arm_group_label>
    <other_name>Focus Dailies Toric All Day Comfort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Filcon II 3</intervention_name>
    <description>a daily disposable</description>
    <arm_group_label>etafilcon A / nelfilcon A / Filcon II 3</arm_group_label>
    <arm_group_label>nelfilcon A / etafilcon A / Filcon II 3</arm_group_label>
    <other_name>Clariti(TM) 1 day Toric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be greater than or equal to 18 years old.

          -  Read, understand, and sign written Statement of Informed Consent.

          -  Appear able and willing to adhere to the instructions set forth in this clinical
             protocol.

          -  Be existing soft contact lens wearers (no extended wear in the last 3 months, but
             silicone hydrogels in daily wear are allowed).

          -  Require a visual correction in both eyes (monovision allowed but no monofit).

          -  Have a spherical contact lens requirement in the range -0.50D to -6.00D.

          -  Have astigmatism of between -0.50 and -2.00DC in both eyes.

          -  Monocular distance visual acuity correctable to 6/9 (0.2 logMAR) or better in each
             eye with best sphero-cylindrical refraction.

          -  Have normal eyes with no evidence of any ocular abnormality or disease. For the
             purposes of this study a normal eye is defined as one having: Clear cornea, No
             anterior segment disorder, No clinically significant slit lamp findings (i.e. oedema,
             staining, scarring, vascularisation, infiltrates or abnormal opacities), No other
             active ocular disease or recent surgery

        Exclusion Criteria:

          -  Having worn RGP contact lenses within the last 30 days or PMMA contact lenses within
             the last 3 months.

          -  Clinically significant corneal oedema, corneal vascularisation, corneal staining,
             tarsal abnormalities, bulbar injection or any other abnormality of the cornea that
             would contraindicate contact lens wear.

          -  Extended lens wear in last 3 months.

          -  Any systemic or topical medications that will in the investigator's opinion affect
             ocular physiology or contact lens performance.

          -  Any systemic disease affecting ocular health.

          -  Abnormal lacrimal secretions.

          -  Keratoconus or other corneal irregularity.

          -  Pregnancy, lactating or planning a pregnancy at the time of enrolment.

          -  Participation in any concurrent clinical trial.

          -  Any previous anterior ocular surgery.

          -  Subjects who are known to have an infectious systemic disease (e.g., hepatitis,
             tuberculosis).

          -  Subjects who are known to have an immunosuppressive disease (e.g., HIV positive).

          -  Subjects who are known to have diabetes.

          -  Employees or family members of the Research site, Principal Investigator or study
             team.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Farnham</city>
        <zip>GU9 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 6, 2015</lastchanged_date>
  <firstreceived_date>March 9, 2012</firstreceived_date>
  <firstreceived_results_date>October 30, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects are considered to be enrolled and not randomized at baseline. There were 42 subjects enrolled and 2 that were not randomized for a study baseline population of 40.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Etafilcon A/ Nelfilcon A/Filcon II 3</title>
          <description>etafilcon A worn first, nelfilcon A worn second, Filcon II 3 worn third. Only etafilcon A and nelfilcon A were used in phase I of the study per study protocol, with Filcon II 3 being added to the rotation in Phase II (see outcome 5).</description>
        </group>
        <group group_id="P2">
          <title>Nelfilcon A/ Etafilcon A/ Filcon II 3</title>
          <description>nelfilcon A worn first, etafilcon A worn second, Filcon II 3 worn third. Only etafilcon A and nelfilcon A were used in phase I of the study per study protocol, with Filcon II 3 being added to the rotation in Phase II (see outcome 5).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects who were enrolled at baseline.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.45" spread="12.707"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I: Absolute Lens Rotation</title>
        <description>At 1-min after lens insertion, lens orientation position was assessed on a scale of 0-180 degree on both eyes.</description>
        <time_frame>At 1-min after lens insertion during Phase I</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects included in the analysis were those who were enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>Those subjects who wore etafilcon A.</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>Those subjects who wore nelfilcon A.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phase I: Absolute Lens Rotation</title>
            <description>At 1-min after lens insertion, lens orientation position was assessed on a scale of 0-180 degree on both eyes.</description>
            <units>Degrees</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.73" lower_limit="5.29" upper_limit="8.56"/>
                  <measurement group_id="O2" value="11.38" lower_limit="8.95" upper_limit="14.48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Time to Lens Settling</title>
        <description>With random insertion and natural blinking, the slit lamp video was used to measure the time of lens settling.</description>
        <time_frame>5 minutes after lens insertion during Phase I</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects analyzed were those who were enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>Those who wore etafilcon A.</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>Those who wore nelfilcon A.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phase I: Time to Lens Settling</title>
            <description>With random insertion and natural blinking, the slit lamp video was used to measure the time of lens settling.</description>
            <units>minutes</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.60" lower_limit="1.25" upper_limit="2.04"/>
                  <measurement group_id="O2" value="1.82" lower_limit="1.43" upper_limit="2.32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase I: Number of Blinks Until Settled</title>
        <description>Number of blinks for the right eye was counted until lens settling using headcam video.</description>
        <time_frame>Baseline to 5 minutes during Phase I</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects analyzed are those who were enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>Those who wore etafilcon A.</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A.</title>
            <description>Those who wore nelfilcon A.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phase I: Number of Blinks Until Settled</title>
            <description>Number of blinks for the right eye was counted until lens settling using headcam video.</description>
            <units>Blinks</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57.29" spread="6.65"/>
                  <measurement group_id="O2" value="74.73" spread="4.56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase I: Absolute Lens Rotation</title>
        <description>Lens orientation position as assessed on a scale of 0-180 on both eyes.</description>
        <time_frame>3 min after lens insertion during Phase I</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was on those subjects who were enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>Those subjects who wore etafilcon A.</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>Those subjects who wore nelfilcon A.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phase I: Absolute Lens Rotation</title>
            <description>Lens orientation position as assessed on a scale of 0-180 on both eyes.</description>
            <units>Degrees</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.26" lower_limit="4.92" upper_limit="7.97"/>
                  <measurement group_id="O2" value="11.06" lower_limit="8.70" upper_limit="14.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Phase II: Absolute Rotation</title>
        <description>Absolute rotation of the lens (degrees) at 1-minute post-fit on both eyes. Filcon II 3 lens was only used for comparison in phase II of the study per study protocol.</description>
        <time_frame>1-minute during Phase II</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was on those subjects who were enrolled, randomized, and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>Those who wore etafilcon A.</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>Those who wore Nelfilcon A</description>
          </group>
          <group group_id="O3">
            <title>Filcon II 3</title>
            <description>All subjects wore the Filcon II 3 lens after the wearing of the etafilcon and nelfilcon lenses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="80"/>
                  <measurement group_id="O3" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phase II: Absolute Rotation</title>
            <description>Absolute rotation of the lens (degrees) at 1-minute post-fit on both eyes. Filcon II 3 lens was only used for comparison in phase II of the study per study protocol.</description>
            <units>Degrees</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.99" spread="14.194"/>
                  <measurement group_id="O2" value="17.54" spread="17.431"/>
                  <measurement group_id="O3" value="16.59" spread="30.820"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>two phases, noted as phase I and phase II</desc>
      <group_list>
        <group group_id="E1">
          <title>Etafilcon A</title>
          <description>Those subjects who wore etafilcon A. (Phase I &amp; II)</description>
        </group>
        <group group_id="E2">
          <title>Nelfilcon A</title>
          <description>Those subjects who wore nelfilcon A. (Phase I &amp; II)</description>
        </group>
        <group group_id="E3">
          <title>Filcon II 3</title>
          <description>Those who wore Filcon II 3 during Phase II</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katherine Osborn OD, MS FAAO</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care</organization>
      <phone>1 904 443-1032</phone>
      <email>kosborn@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
